vs
Side-by-side financial comparison of TRANSCONTINENTAL REALTY INVESTORS INC (TCI) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $12.1M, roughly 1.1× TRANSCONTINENTAL REALTY INVESTORS INC). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs 68.8%, a 6.9% gap on every dollar of revenue.
Transcontinental Realty Investors Inc. (TCI) is a U.S.-based real estate investment firm that owns, operates and develops a diversified portfolio of residential, commercial and mixed-use properties across core U.S. regional markets. It pursues long-term value growth via strategic property acquisitions, efficient asset management and tailored leasing solutions for individual and business tenants.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
TCI vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.1M | $13.7M |
| Net Profit | $8.3M | $10.4M |
| Gross Margin | — | — |
| Operating Margin | -28.9% | -86.5% |
| Net Margin | 68.8% | 75.7% |
| Revenue YoY | 2.3% | — |
| Net Profit YoY | 7577.8% | 179.1% |
| EPS (diluted) | $0.97 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.1M | $13.7M | ||
| Q3 25 | $12.8M | $19.1M | ||
| Q2 25 | $12.2M | $8.1M | ||
| Q1 25 | $12.0M | $2.9M | ||
| Q4 24 | $11.8M | — | ||
| Q3 24 | $11.6M | — | ||
| Q2 24 | $11.8M | — | ||
| Q1 24 | $11.9M | — |
| Q4 25 | $8.3M | $10.4M | ||
| Q3 25 | $724.0K | $-16.3M | ||
| Q2 25 | $169.0K | $-15.8M | ||
| Q1 25 | $4.6M | $-13.3M | ||
| Q4 24 | $108.0K | — | ||
| Q3 24 | $1.7M | — | ||
| Q2 24 | $1.5M | — | ||
| Q1 24 | $2.5M | — |
| Q4 25 | -28.9% | -86.5% | ||
| Q3 25 | -10.9% | -10.1% | ||
| Q2 25 | -6.8% | -177.7% | ||
| Q1 25 | -5.3% | -472.7% | ||
| Q4 24 | -14.3% | — | ||
| Q3 24 | -14.4% | — | ||
| Q2 24 | -9.2% | — | ||
| Q1 24 | -11.2% | — |
| Q4 25 | 68.8% | 75.7% | ||
| Q3 25 | 5.6% | -85.4% | ||
| Q2 25 | 1.4% | -196.0% | ||
| Q1 25 | 38.5% | -452.7% | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | 14.7% | — | ||
| Q2 24 | 12.7% | — | ||
| Q1 24 | 21.4% | — |
| Q4 25 | $0.97 | $-3.74 | ||
| Q3 25 | $0.08 | $-0.11 | ||
| Q2 25 | $0.02 | $-0.16 | ||
| Q1 25 | $0.53 | $-0.18 | ||
| Q4 24 | $0.01 | — | ||
| Q3 24 | $0.20 | — | ||
| Q2 24 | $0.17 | — | ||
| Q1 24 | $0.30 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.0M | $137.5M |
| Total DebtLower is stronger | $210.8M | — |
| Stockholders' EquityBook value | $846.7M | $35.3M |
| Total Assets | $1.1B | $154.7M |
| Debt / EquityLower = less leverage | 0.25× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.0M | $137.5M | ||
| Q3 25 | $82.7M | $103.8M | ||
| Q2 25 | $73.5M | $121.6M | ||
| Q1 25 | $88.6M | $89.1M | ||
| Q4 24 | $99.7M | — | ||
| Q3 24 | $131.6M | — | ||
| Q2 24 | $127.5M | — | ||
| Q1 24 | $130.8M | — |
| Q4 25 | $210.8M | — | ||
| Q3 25 | $223.5M | — | ||
| Q2 25 | $212.4M | — | ||
| Q1 25 | $198.2M | — | ||
| Q4 24 | $181.9M | — | ||
| Q3 24 | $180.3M | — | ||
| Q2 24 | $177.4M | — | ||
| Q1 24 | $178.3M | — |
| Q4 25 | $846.7M | $35.3M | ||
| Q3 25 | $838.4M | $-8.1M | ||
| Q2 25 | $837.7M | $7.1M | ||
| Q1 25 | $837.3M | $10.7M | ||
| Q4 24 | $832.3M | — | ||
| Q3 24 | $832.2M | — | ||
| Q2 24 | $830.4M | — | ||
| Q1 24 | $828.9M | — |
| Q4 25 | $1.1B | $154.7M | ||
| Q3 25 | $1.1B | $133.7M | ||
| Q2 25 | $1.1B | $133.8M | ||
| Q1 25 | $1.1B | $103.7M | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $1.0B | — |
| Q4 25 | 0.25× | — | ||
| Q3 25 | 0.27× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 0.24× | — | ||
| Q4 24 | 0.22× | — | ||
| Q3 24 | 0.22× | — | ||
| Q2 24 | 0.21× | — | ||
| Q1 24 | 0.22× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.9M | $-2.0M |
| Free Cash FlowOCF − Capex | — | $-2.1M |
| FCF MarginFCF / Revenue | — | -15.3% |
| Capex IntensityCapex / Revenue | — | 0.7% |
| Cash ConversionOCF / Net Profit | -0.35× | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.9M | $-2.0M | ||
| Q3 25 | $8.2M | $-17.5M | ||
| Q2 25 | $-2.9M | $-14.5M | ||
| Q1 25 | $-7.4M | $29.0M | ||
| Q4 24 | $1.3M | — | ||
| Q3 24 | $13.7M | — | ||
| Q2 24 | $-511.0K | — | ||
| Q1 24 | $3.9M | — |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-14.9M | ||
| Q1 25 | — | $29.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -15.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -184.0% | ||
| Q1 25 | — | 988.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.7% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 5.0% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -0.35× | -0.19× | ||
| Q3 25 | 11.28× | — | ||
| Q2 25 | -17.24× | — | ||
| Q1 25 | -1.61× | — | ||
| Q4 24 | 12.13× | — | ||
| Q3 24 | 8.03× | — | ||
| Q2 24 | -0.34× | — | ||
| Q1 24 | 1.52× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
